In-vitro and in-vivo evaluation of austocystin D liposomes

Objectives The purpose this study is to enhance the anti-tumour activity of austocystin D (AD) by AD-loaded liposomes (AD-Ls). Methods AD-Ls were prepared by the film dispersionultrasonication method and characterized in terms of particle size and zeta potential, encapsulation efficiency and in-vitro drug release. In vivo, the pharmacokinetics, biodistribution and anti-tumour effect were also compared with those of the solution. Key findings The obtained liposomes were a mildly translucent suspension, with a particle size of 71.26?+/-?6.43?nm, a polydispersity index of 0.259?+/-?0.017 and a zeta potential of -9.9?+/-?1.8?mV. Transmission electron microscope examination showed that the liposomes had a spherical shape and a multilayer structure. The encapsulation efficiency ofAD-Ls was 83.74?+/-?1.26%. AD was continuously released from liposomes up to 72?h in in-vitro experiments. The growth of HT-29 tumours in animal models was controlled more effectively by AD-LS than by AD solution. Pharmacokinetic study showed that AD-Ls had higher t 1/2 beta and mean retention time. Biodistribution results in tumour-bearing mice showed that the AD-LS could target to liver and tumour. Conclusions This study indicates that AD-Ls are a potential carrier of AD for the treatment of tumours in the liver, increasing the cure efficiency and decreasing the side effects on other tissues.